Suppr超能文献

三层微囊作为一种长效缓释注射制剂。

Three-layered microcapsules as a long-term sustained release injection preparation.

机构信息

Department of Pharmacokinetics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan.

出版信息

Int J Pharm. 2010 Jan 15;384(1-2):53-9. doi: 10.1016/j.ijpharm.2009.09.032. Epub 2009 Sep 25.

Abstract

Three-layered milli-capsules (3LMC), diameter of 1.85+/-0.07 and 0.15+/-0.09 mm thickness, were designed for the long-term subcutaneous (sc) administration of drugs. 3LMCs composed of (1) surface membrane (release rate control membrane), (2) drug-carrying layer and (3) base membrane were prepared by dispensing each solution in series. As surface membrane, poly-(epsilon-caprolactone) having MW of 70 kDa (PCL70) was used in combination with plasticizer, polysorbate 60 (Tween60). Base membrane was prepared with PCL70. Fluorescein isothiocyanate labeled dextrans (FD-4, MW=4 kDa and FD-20, MW=20 kDa) were used as model drug and in vitro release experiment was performed with PCL70 surface membrane containing Tween60 with 0.3, 1.0 and 3.0% (w/w). As the amount of Tween60 increased, release rate of FD-4 was increased. PCL70+0.3% Tween60 membrane showed a good sustained release property for 5 weeks; 50.3+/-6.0% of FD-4 was released during 5 weeks. When FD-20 was encapsulated, long-term sustained release was not obtained, 10.7+/-3.6% was released during 5 weeks. However, when lower MW drug, leuprolide acetate, was encapsulated, 3LMC composed of PCL70+0.3% Tween60 showed a good sustained release property, 63.0+/-5.9% released for 5 weeks. Leuprolide acetate encapsulated 3LMC was evaluated in rat experiment. After sc administration to rats, 0.5 and 1.0 mg, plasma leuprolide concentration showed its maximum concentration at day 1, thereafter gradually decreased and maintained the effective concentration for 14 weeks. Plasma leuprolide concentration vs. time curve showed a good dose-dependency. When surface membrane prepared by blending PCL70 and poly(lactic acid) (PLA) in the molar ratio of 5:1 was used, long-term sustained release property was not obtained. Instead, lower MW PCL, PCL40, was blended with PLA (5:1) to prepare surface membrane, sustained release of leuprolide was observed for 5 weeks. Through those studies, 3LMC has been shown to be a long-term sustained release preparation by properly selecting the surface membrane.

摘要

三层毫微胶囊(3LMC),直径为 1.85+/-0.07 毫米和 0.15+/-0.09 毫米厚度,被设计用于药物的长期皮下(sc)给药。3LMC 由(1)表面膜(释放速率控制膜)、(2)载药层和(3)基膜组成,通过依次分配各溶液来制备。作为表面膜,使用具有 70 kDa(PCL70)分子量的聚己内酯(PCL70)与增塑剂聚山梨醇酯 60(Tween60)结合使用。基膜由 PCL70 制备。荧光素异硫氰酸酯标记的葡聚糖(FD-4,分子量=4 kDa 和 FD-20,分子量=20 kDa)被用作模型药物,并在含有 0.3、1.0 和 3.0%(w/w)Tween60 的 PCL70 表面膜中进行体外释放实验。随着 Tween60 量的增加,FD-4 的释放速率增加。PCL70+0.3%Tween60 膜在 5 周内表现出良好的持续释放性能;在 5 周内释放了 50.3+/-6.0%的 FD-4。当包封 FD-20 时,没有获得长期持续释放,在 5 周内释放了 10.7+/-3.6%。然而,当包封低分子量药物醋酸亮丙瑞林时,由 PCL70+0.3%Tween60 组成的 3LMC 表现出良好的持续释放性能,在 5 周内释放了 63.0+/-5.9%。醋酸亮丙瑞林包封的 3LMC 在大鼠实验中进行了评估。在 sc 给予大鼠 0.5 和 1.0 mg 后,血浆亮丙瑞林浓度在第 1 天达到最高浓度,此后逐渐下降并维持 14 周的有效浓度。亮丙瑞林的血浆浓度与时间曲线显示出良好的剂量依赖性。当使用 PCL70 和聚乳酸(PLA)以摩尔比 5:1 混合制备表面膜时,未获得长期持续释放性能。相反,将较低分子量的 PCL(PCL40)与 PLA(5:1)混合以制备表面膜,观察到亮丙瑞林的持续释放长达 5 周。通过这些研究,通过适当选择表面膜,已经证明 3LMC 是一种长效持续释放制剂。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验